Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Kumquat Biosciences Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals sector with 2 pending office actions. These actions are spread across 2 distinct examiners and 2 distinct art units. This suggests the company's pending applications cover diverse technical aspects within its primary Biotechnology & Pharmaceuticals technology area.
The busiest examiner, BARSKY, JARED, is currently handling 1 pending office action. With a total of 2 pending office actions, the workload is shared among 2 distinct examiners, each managing a single case. This structure means that the prosecution strategy must account for the specific requirements of 2 different art units simultaneously.
For a patent practitioner, the involvement of 2 distinct examiners indicates that the company's Biotechnology & Pharmaceuticals portfolio is not centralized under one individual. Each of the 2 pending office actions will follow its own trajectory based on the 2 distinct art units involved. The 1 pending office action managed by BARSKY, JARED represents half of the current active prosecution for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.2% | +22.9% |
| AEDER, SEAN E | 1 | 56.9% | +19.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506478 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BARSKY, JARED | — |
| 18297211 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | AEDER, SEAN E | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18506478 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BARSKY, JARED | 1628 | §112DP | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18297211 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | AEDER, SEAN E | 1642 | §103 | Non-Final OA | — | Pending | Apr 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKumquat Biosciences Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Jared Barsky has the most, with 1 of Kumquat Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.